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Abstract
In tumor cells, stepwise oncogenic deregulation of signaling cascades induces alterations of cellular morphology and
promotes the acquisition of malignant traits. Here, we identified a set of 21 genes, including FGF9, as determinants of tumor
cell morphology by an RNA interference phenotypic screen in SW480 colon cancer cells. Using a panel of small molecular
inhibitors, we subsequently established phenotypic effects, downstream signaling cascades, and associated gene
expression signatures of FGF receptor signals. We found that inhibition of FGF signals induces epithelial cell adhesion and
loss of motility in colon cancer cells. These effects are mediated via the mitogen-activated protein kinase (MAPK) and Rho
GTPase cascades. In agreement with these findings, inhibition of the MEK1/2 or JNK cascades, but not of the PI3K-AKT
signaling axis also induced epithelial cell morphology. Finally, we found that expression of FGF9 was strong in a subset of
advanced colon cancers, and overexpression negatively correlated with patients’ survival. Our functional and expression
analyses suggest that FGF receptor signals can contribute to colon cancer progression.
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Introduction
Late steps of tumor progression can result in metastatic
dissemination of tumor cells, which have lost epithelial character-
istics and acquired migratory and invasive capabilities. Morpho-
logically, this phenotypic switch resembles the conversion of
stationary epithelial cells into migratory mesenchymal cells during
embryonic development, and therefore all of these processes are
frequently termed epithelial-to-mesenchymal transition (EMT)
[1,2,3,4,5]. Key steps in developmental and tumor-associated
EMT are loss of E-Cadherin-based cell adhesion (by epigenetic
silencing or transcriptional repression of CDH1, coding for E-
Cadherin), reorganisation of the cytoskeleton leading to altered
cell morphology, and induction of mesenchymal-specific gene
expression, such as activation of FN1 and VIM [6,7,8,9,10,11]. In
the embryo, EMT occurs in an ordered and highly reproducible
manner. In tumor cells, however, EMT-like phenomena can be
temporary, chaotic and incomplete.
In the embryo, EMT is induced by coordinated activation of
signaling pathways, while in tumor cells complete or partial EMT
can be elicited by the combined activities of oncogenic mutations
and growth factor signals received from within the tumor cell
microenvironment. Still, roles of key signaling pathways and
molecules appear to be conserved. For instance, b-Catenin is
required for the first embryonic EMT leading to formation of the
primitive streak and mesoderm [12], while in colon carcinoma and
other tumors b-Catenin transduces key signals at the invasive
front, leading to loss of tumor cell adhesion, induction of cell
motility and metastasis [13,14,15]. Multiple receptor tyrosine
kinases (RTK) have been implicated in both, developmental and
tumor-associated EMT. In embryonic development, the scatter
factor/hepatocyte growth factor receptor MET is essential for
migration of muscle progenitor cells, the epidermal growth factor
(EGF) receptor is required for epithelial morphogenesis [16,17,18],
and the fibroblast growth factor (FGF) receptor Fgfr1 and its
ligand Fgf8 are essential for cell migration through the primitive
streak and mesoderm formation [19,20]. In tumors, unphysiolog-
ical signaling through RTKs such as MET, the vascular
endothelial growth factor (VEGF) receptor, and the EGF and
FGF receptors can be associated with progression and metastasis
[21,22]. Importantly, the EGF and VEGF receptors are targets for
rational therapy of advanced colon cancer [23].
Mitogen-activated protein kinase (MAPK) pathways, such as the
Jun-N-terminal-kinase (JNK) and the mitogen-activated protein
kinase kinase/extracellular-regulated kinase (MEK/ERK) path-
ways, integrate signals from multiple RTKs to control cell
proliferation, cell motility and other cellular traits [24]. Oncogenic
mutations in genes coding for signal transducers that relay signals
from RTKs to MAPK pathways such as KRAS or BRAF can
sensitize signaling via the MEK/ERK pathway in tumors, and
such mutations invalidate therapeutic intervention strategies at
upstream RTK receptors [25]. Both, during development and in
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tumors, EMT signals are frequently integrated by transcriptional
repressors of CDH1, such as Snail, Snail2, Twist and others, which
thus play important roles in the control of cell morphology and
tumor progression [9,10,26].
Here, we took advantage of the molecular similarity between
developmental and tumor-associated EMT to identify new candi-
date genes involved in colon cancer progression. In an RNA
interference screen we identified multiple genes whose inactivation
promoted an epithelial phenotype and E-Cadherin-mediated cell
adhesion in SW480 colon cancer cells. Many of the genes identified
code for components of key signaling pathways, such as the Wnt,
Hedgehog and RTK pathways, for instance FGF9, PTCH1, GLI2,
GLI3 and TCF7L1. Using the identification of FGF9 as a lead, we
found that FGFR signals play roles in loss of colon cancer cell
adhesion and induction of cell motility. To mediate these effects,
FGFR signals modulate theMEK/ERK cascade and RhoGTPases.
Our results thus identify FGFR signals as major determinants of the
MEK/ERK cascade activity in SW480 colon cancer cells, even in
the presence of an oncogenic KRAS mutation. We found that FGF9
was expressed in colon cancer and expression levels correlate with
patient survival, suggesting a functional role in the cancer.
Results
An RNAi interference phenotypic screen for genes that
regulate colon tumor progression
Invasive growth and metastasis of tumors involves loss of
epithelial cell adhesion and gain of cell motility. We reasoned that
genes whose products play roles in tumor progression may be
enriched among those expressed in the caudal end of the mid-
gestation mouse embryo, a place where epithelial cells undergo
developmental EMT, i.e. a phenotypic switch to a mesenchymal
state of low cell adhesion and high cell motility. We therefore used
the MAMEP database (http://mamep.molgen.mpg.de) and liter-
ature searches to compile a list of genes expressed preferentially in
the caudal end of the mid-gestation (E9.5) embryo, and identified
their human homologues. Next, we targeted these genes using
esiRNAs [27] in SW480 human colon cancer cells, which display a
mesenchymal (‘‘spindle-form’’) morphology, are motile and have
little cell adhesion. We screened for genes whose inactivation
promoted epithelial (‘‘cobblestone’’) cell morphology and locali-
zation of the epithelial cell adhesion molecule E-Cadherin to cell-
cell contacts (Fig. 1A). Out of 364 genes screened, silencing of 18
candidates induced epithelial morphology comparable to interfer-
ence with the reference BCL9L, which is a transcriptional co-
activator of b-Catenin [28]. We also found three genes whose
inactivation promoted a more spindle-form cell morphology. In
contrast, control-transfected cells did not display consistent
morphological changes (Fig. 1B; for interference efficacy, see
Fig. S1; for a complete list of targeted genes and positives, see
Table S1 and Table 1, respectively).
Many of the identified genes play known roles in the control of
signaling pathways that regulate embryonic development, organ
homeostasis, and tumor progression. We found TCF7L1, coding
for a downstream transcription factor of the Wnt/b-Catenin
signaling cascade [29], as well as the Wnt/b-Catenin signaling
components SFRP1 and CSNK2A1. We also isolated PTCH1, GLI2,
and GLI3, which code for components of the Hedgehog signaling
pathway [30]. We found FGF9 and EPHA4, coding for an RTK
ligand and a RTK of the ephrin subfamily regulating cell adhesion
and the cytoskeleton via MAPK and Rho [31,32]. The candidate
gene TAX1BP3 may also have roles in the regulation of Rho
signals [33]. Among several genes implicated in the regulation of
transcription, we found SIX1, coding for a homeobox transcription
factor implicated in cell differentiation and tumor progression
[34,35] (Fig. 2).
FGF signals regulate adhesion and motility of colon
cancer cells
Since we identified FGF9 in our cellular screen and found
expression of FGF9 in intestinal malignancies of both mouse and
humans (see below), we focused on the roles of FGF signals in
colon carcinoma cells. First, we confirmed the screening result
using an independent FGF9 siRNA preparation, which likewise
induced an epithelial phenotype in SW480, i. e. led to a loss of
spindle-form cells and to an increase in membraneous E-Cadherin
staining (Fig. S2). In another colon cancer cell line, HCT116,
silencing of FGF9 had no apparent effect. However, when we
targeted FGFR3, coding for a high affinity receptor of FGF9 and
other FGFs, we found that it promoted epithelial cell morphology
in HCT116 (Fig. S2). These findings indicate that FGF receptor
signals may commonly have roles in the control of colon cancer
cell morphology, and that different pathway components may be
limiting in the various cell lines.
Next, we targeted the FGF receptors using the small molecule
inhibitor SU5402 [36], and assessed changes in the cellular
phenotype. In agreement with our RNA interference data, inhibition
of FGF receptors promoted epithelial morphology of SW480 cells
and commanded E-Cadherin and b-Catenin to cell-cell contacts,
indicating de-novo assembly of epithelial adherens junctions (Fig. 3A).
Similar effects were observed on the morphology of SW620 cells,
which are derived from the same patient, and on HT29 and
HCT116 cells, which are derived from other patients (Fig. S3).
Cell adhesion and cell motility are often inversely correlated in
tumor cells. We therefore also assessed cell motility. Control
SW480 cells rapidly migrated, whereas SU5402-treated cells could
no longer close a scratch wound (Fig. 3B). FGF receptor-inhibited
cells at the scratch edge displayed increased staining of cortical
actin and reduced numbers of focal adhesion contacts, indicating
altered dynamics of the cytoskeleton (Fig. 3C). Furthermore, Rho
GTPases, which are key effectors of the balance between cell
adhesion and motility [37], appeared localized to nuclear speckles
in SW480 cells invading the scratch, and were reduced in
inhibitor-treated SW480 cells (Fig. 3D). Cell proliferation was only
mildly affected by FGF receptor inhibition (Fig. 3E). We saw
similar effects on cell morphology and motility using a structurally
unrelated small molecule inhibitor of FGF receptors, PD173074
(data not shown). These results indicate that FGF receptor signals
can play essential roles in the switch from a stationary to a
migratory phenotype, which is a hallmark of the late steps of
intestinal tumor progression resulting in metastasis.
FGF signals in colon cancer cells are transmitted via the
MAPK pathway and Rho
FGF receptor signals are known to be transmitted via MAPK
cascades and via the phosphoinositid-3-kinase (PI3K)/AKT
signaling cascade [38]. We therefore analyzed the activity of key
cellular signal transducers after inhibition of FGF receptors or key
downstream signal transducers, i.e. U0126, inhibiting the MEK1/
2 kinases of the classical MEK/ERK MAPK cascade, SP600125,
an inhibitor of the alternative JNK cascade and LY294002, an
inhibitor of PI3K signal transduction. As expected, inhibition of
MEK1/2 abolished phosphorylation of ERK1/2, and inhibition
of PI3K abolished phosphorylation of AKT. Upon FGF receptor
inhibition, we found a limited, but reproducible reduction of
ERK1/2 phosphorylation (of about 30%). In contrast, the activity
of p85-PI3K was not affected. Changes in the phosphorylation of
FGF Signals in Colon Cancer Progression
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AKT indicated that additional signal transduction networks are
modulated directly or indirectly when inhibiting FGF receptors or
JNK (Fig. 4A, B).
We next tested phenotypic effects of inhibition of the
downstream cascades. Treatment of SW480 cells with U0126
(inhibiting MEK1/2) or with SP600125 (inhibiting JNK) support-
ed the formation of epithelial cell adhesion complexes, and
blocked cell motility, similar to effects seen after inhibition of FGF
receptor signals (Fig. 4C, Fig. S4). In contrast, phenotypes
observed after treatment with LY294002 (inhibiting PI3K) or
the Calbiochem AKT-Inhibitor were not comparable with effects
seen after FGF receptor inhibition (Fig. 4C). A similar correlation
of cellular phenotypes upon inhibition of signaling hubs was
observed in HCT116 cells, which however did not display
modulation of E-cadherin localization under any conditions (Fig.
S5, see also Fig. S2). In summary, these results indicate that FGFR
signals modulate activity of the MEK/ERK signaling cascade in
SW480 cells, and that activity of FGFR, MEK1/2 and JNK are
required for the maintenance of a phenotype that favors cell
motility over cell adhesion.
Since we observed re-localization of Rho in motile SW480 cells
(see above, Fig. 3D), we determined the impact of FGFR orMEK1/
2 signals on Rho activity, using Rho loading assays. For this, we
serum-starved SW480 cells for 24 h, and assessed Rho activation
after serum re-stimulation. Addition of serum led to rapid induction
of active Rho-GTP in control cells, while Rho activation was
compromised in the presence of FGF receptor or MEK1/2
inhibitors (Fig. 4D). This result suggests that in SW480 cells FGF
receptors and MEK1/2 play roles in the regulation of Rho
GTPases, which are central in modulation of the cytoskeleton.
FGFR and MAPK signals are associated with specific gene
expression signatures
To isolate gene expression signatures related to FGFR signals
and cell motility in colon cancer cells, we compared gene
expression profiles of solvent control and inhibitor-treated
Figure 1. An RNA interference phenotypic screen in SW480 colon cancer cells. A Schematic overview of the screen: Genes were selected by
screening the MAMEP database (http://mamep.molgen.mpg.de) for genes that display caudally restricted expression in the mouse embryo and
literature searches. Example images of such gene expression patterns are displayed on top of the flow chart. Human homologues were inactivated by
RNA interference in SW480 cells. Positive genes were identified by their ability to promote epithelial cell morphology. B E-Cadherin distribution and
morphology of SW480 cells transfected with esiRNA against firefly luciferase (Fluc, negative control), BCL9L (positive control) and several positive
genes. Genes marked with (*) induced a more spindle-form morphology. Scale bars represent 50 mm. For a full list of genes targeted in the screen, see
Table S1. For a full list of genes that scored positive, see Table 1.
doi:10.1371/journal.pone.0023381.g001
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SW480 cells. We first used functional clustering of genes
deregulated between control (DMSO-treated) and SU5402-
treated cells using Ingenuity pathway analysis (IngenuityH Systems,
www.ingenuity.com). Among the signaling networks most strongly
affected, we identified a cluster of deregulated genes related to cell
motility that centers on the ERK1/2-dependent MAPK pathway,
corroborating our previous results (Fig. S6). The inferred network
contains central signal transducers of motility signals such as
ERK1/2 and PTK2 (focal adhesion kinase), and converges on the
transcription factors JUN/JUNB and FOSL1. Importantly, FOSL1
has previously been identified as a key transcription factor in the
control of tumor cell motility [39].
Next, we compared DMSO-treated and PI3K-inhibitor-treated
SW480 cells (displaying mesenchymal ‘‘spindle-form’’ morphology
and weak cell adhesion) with FGFR-inhibitor-, MEK1/2-inhibitor
and JNK-inhibitor treated cells (displaying epithelial ‘‘cobble-
stone’’ morphology and strong cell adhesion, see also Fig. 4C). We
used self-organizing maps to identify groups of genes whose
expression is associated with these distinct morphologies, and
identified 29 genes which were associated with strong cell adhesion
and 23 genes associated with weak cell adhesion. Signature genes
of SW480 cells that have strong cell adhesion were RAP1GAP,
which is involved in the assembly of adherens junctions and
CLDN1, a component of adherens junctions, providing evidence
that epithelial cell adhesion is regulated at least partly on the
transcriptional level. We also found enhanced expression of the
transcription factor genes ELF3 and HMGCS2, which play
functional roles in epithelial differentiation [40,41], the tumor
suppressors SYK and TFAP2C and the Rho regulator ARHGEF37.
Table 1. Genes identified as positives in the RNA interference phenotypic screen in SW480 cells.
Ensembl ID Gene Symbol Molecular Function
ENSG00000137936 BCAR3 Adaptor protein with RasGEF domain
ENSG00000101266 CSNK2A1 Serine/threonine kinase
ENSG00000157557 ETS2 Transcription factor
ENSG00000048828 FAM120A unknown (RNA-binding)
ENSG00000102678 FGF9 Fibroblast growth factor receptor ligand
ENSG00000128683 GAD1 Glutamate decarboxylase
ENSG00000074047 GLI2 Transcription factor (Hedgehog signaling)
ENSG00000106571 GLI3 Transcription factor (Hedgehog signaling)
ENSG00000061273 HDAC7 Histone deacetylase
ENSG00000117114 LPHN2 G-Protein coupled receptor
ENSG00000139946 PELI2 Scaffolding protein (MAPK signaling)
ENSG00000117707 PROX1 Homeobox transcription factor
ENSG00000185920 PTCH1 Hedgehog receptor
ENSG00000104332 SFRP1 Secreted modulator of Wnt activity
ENSG00000126778 SIX1 Homeobox transcription factor
ENSG00000005513 SOX8 HMG-Box transcription factor
ENSG00000108392 TAX1BP3 unknown, may play roles in Rho and/or Wnt signaling
ENSG00000152284 TCF7L1 HMG-Box transcription factor (Wnt signaling)
ENSG00000122870 BICC1* unknown (Putative RNA-binding)
ENSG00000116106 EPHA4* Receptor tyrosine kinase
ENSG00000151276 MAGI1* Scaffolding protein (Cell-cell adhesion)
Ensembl ID, Gene Symbol and molecular function of genes whose inactivation induced a more epithelial phenotype is given. Entries marked with (*) at the end of the
list represent genes whose inactivation induced a stronger mesenchymal phenotype. Molecular function was retrieved using the Genecards database (http://www.
genecards.org).
doi:10.1371/journal.pone.0023381.t001
Figure 2. Pathway assignment of genes that scored positive in
the RNA interference phenotypic screen. Gene symbols of
positives are given in black letters, associated key pathway components
are given in grey letters, displayed in colored circles and ordered by
cellular compartment. Blue: Wnt pathway, Green: Hedgehog pathway,
Cyan: RTK pathways. Genes were assigned to pathways using literature,
Gene ontology and other database searches. Key references are given in
the main text.
doi:10.1371/journal.pone.0023381.g002
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Signature genes of SW480 cells that have weak cell adhesion and
mesenchymal morphology were enriched for genes that have been
assigned oncogenic activity, namely EDN1, IGFBP7,MCM5,MFI2
and TNFAIP8. Finally, we also found TAX1BP3, which we above
isolated in our phenotypic esiRNA screen, suggesting a functional
role for this gene in the regulation of adhesion and motility
(Fig. 5A) [33]. We observed a similar pattern of gene regulation
upon FGF receptor inhibition in HCT116 colon cancer cells
(which displayed loss of spindle form upon FGFR3 RNA
interference or FGF receptor inhibition, see Fig. S2, S3),
Figure 3. FGF receptor signals are essential for SW480 cell motility. A Phenotypic switch of SW480 cells upon FGF receptor inhibition by
SU5402. Top to bottom: Cell morphology in bright field, immunostaining of E-Cadherin and b-Catenin. Photos were taken 72 h after start of SU5402
treatment. Below: SW480 cells receive FGF signals, which can be blocked by SU5402. B Scratch-wound motility assay upon FGF receptor inhibition.
SW480 cells were grown to confluence, and scratches were induced 24 h after start of treatment. Bright field images of the scratch edge were taken
24, 48 and 72 hour after scratching. Scale bars in A and B represent 50 mm. C, D Immunostaining of the scratch edge. C Staining of the actin and the
microtubule cytoskeleton in control and SU5402-treated cells. Green: actin (phalloidin); yellow: tubulin; blue: nuclei (DAPI); arrows: areas of dense
focal adhesion in motile control cells; arrowheads: enhanced cortical actin staining in SU5402-treated cells. D RhoA redistribution in migrating cells,
which is reduced in inhibitor-treated cells. Green: actin; red: RhoA; blue: nuclei. grey arrowheads mark nuclear RhoA. Dashed line marks scratch edge.
Scale bars in C and D represent 25 mm. E Quantification of proliferation in control and SU5402-treated cells. For time-course of proliferation, cells
were plated in replicates, and duplicate samples were counted bi-daily in a Neubauer hematocytometer.
doi:10.1371/journal.pone.0023381.g003
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implicating a conserved role of this gene cluster downstream of the
FGF receptors (Fig. S7).
When we assessed the expression of key modulators of EMT, we
saw a small, albeit not significant, variation in the expression of
CDH1, indicating that the more drastic changes that we see in E-
Cadherin localization (see Fig. 1B, 3A) occur predominantly via
posttranscriptional regulation. Expression of VIM and TWIST were
only weakly affected, while other EMT markers were found to be
non-expressed. These data suggest that SW480 cells do not undergo a
complete mesenchymal-to-epithelial transition after FGF receptor or
MAPK inhibition. We also did not see regulation of intestinal stem
cell markers, which have recently been linked to EMT in tumors
(Fig. 5B) [42,43,44]. Regulation of the transcriptional repressor
SNAI2 and its target gene CDH1 via ERK1/2 signals has been
demonstrated before in SW480 cells [45]. We therefore assessed the
expression of SNAI2 and CDH1 by qRT-PCR, which can be more
sensitive than array analysis. We could confirm the mild activation of
CDH1 after SU5402 treatment, while SNAI2was unchanged (Fig. 5C).
Figure 4. FGF receptor signals for epithelialization are transmitted via MEK1/2 and Rho. A Analysis of Phospho-ERK1/2, Phospho-P85PI3K
and Phospho-AKT in SW480 cells after treatment with DMSO (solvent control), SU5402 (inhibiting FGFR), U0126 (inhibiting MEK1/2 dependent ERK1/2
phosphorylation), SP600125 (inhibiting JNK), and Ly294002 (inhibiting PI3K-mediated AKT phosphorylation) are shown. Histone H3 is shown as
loading control. Phosphorylation status was assessed 40 minutes after inhibitor treatment. B Quantification of ERK1/2 phosphorylation, mean of
three experiments. C Morphology, E-cadherin immunofluorescence and cell motility of SW480 cells after 72 h of inhibitor treatment. Inhibition of the
classical MAPK or alternative MAPK/JNK cascades induced a similar phenotype as FGFR inhibition in SW480 cells, wheras inhibition of PI3K or AKT had
no such effect. We found that PI3K inhibition, but not AKT inhibition, inhibits cell motility. Uncoupling of PI3K and AKT signals has been observed
before in tumors [56]. Scratch assay was done as in Fig. 3B. Scale bars represent 50 mm. D Inhibition of FGF receptors or MEK1/2 leads to reduced Rho
activity. Rho GTPase loading assays were performed in SW480 cells 5 min after serum stimulation in the presence or absence of SU5402 or UO126.
N.d.: not determined.
doi:10.1371/journal.pone.0023381.g004
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FGF9 expression is correlated with patient’s survival in
human colon cancer
To assess the in-vivo significance of our analyses, we determined
expression of FGF9 in specimen of mouse and human intestinal
tumors. In mouse intestinal adenoma, we found increased
expression of Fgf9 in a similar pattern as the Wnt target gene
Axin2. When we determined expression of FGF9 in human colon
cancer, we likewise found generalized expression in the tumor
epithelium in primary tumors and lung metastases (Fig. 6). Since
our screen, in conjunction with our subsequent functional analysis
of overall FGF signals, indicated a possible role for FGF9 signals in
intestinal carcinoma, we examined the relative expression levels of
Figure 5. Epithelial and mesenchymal phenotypes of SW480 cells correlate with gene expression signatures. A–B Microarray analysis
of SW480 after small molecular inhibition of FGFR, MEK1/2, JNK or PI3K. Average expression of triplicate experiments is displayed. Red: High
expression; Blue: low expression White: Median expression across all profiles Grey: Genes with no or marginal expression A Clusters of genes whose
activity correlates with epithelial and mesenchymal phenotypes. The following procedure was used to identify these genes: First, genes deregulated
more than 1.3fold (p,0.01) after SU5402 treatment compared to control (DMSO) were isolated. Second, these genes were clustered in self-organizing
maps, and three clusters that correlated with the phenotype were selected. Genes were ordered by fold-change expression after FGFR inhibition. B
Assessment of key genes implicated in EMT or stemness. C Quantitative Real-time PCR analysis of SNAI2 and CDH1 after SU5402 (FGFR Inhibitor)
treatment. Expression was normalized to solvent control samples.
doi:10.1371/journal.pone.0023381.g005
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FGF9 in a set of 95 expression profiles of human colon cancer,
comprising normal colon (4 profiles), advanced colon carcinoma
(staged T3/4 by International Union Against Cancer (UICC)
criteria; 41 profiles), and metastases to lymph nodes, liver and lung
(50 profiles) [46]. We found basal expression levels of FGF9 in the
normal colon tissue profiles and in a majority of tumor profiles, but
high expression of FGF9 in a subgroup of 7 colon tumors and 5
metastases (Fig. 7A; cut-off.2-fold compared to normal tissue). Of
note, we also found increased expression of FGFR3, coding for a
high-affinity FGF9 receptor, in 3 primary tumor profiles and
several metastases (Fig. 7A). The high expression of FGF9 was
maintained between pairs of primary tumors and metastases
derived from three patients, indicating that FGF9 activation in the
tumor can persist over long periods of time.
We finally correlated the expression of FGF9 in primary tumors
(n = 39) with patient survival, using Kaplan-Meier analysis. The
subgroup of 7 patients with high expression of FGF9 had
significantly shorter survival compared to patients with low
FGF9 expression (Fig. 7B, p=0.008). We saw a similar result,
when we included the patients with high expression of FGFR3 in
the group (Fig. 7B, p=0.006). The observed correlation between
high expression of FGF9 and short patient survival may indicate
functional roles of FGF9 in tumor progression.
Discussion
Here, we undertook a focused screen to identify genes whose
expression is required to maintain a mesenchymal, potentially
metastatic phenotype in SW480 colon cancer cells, and isolated
multiple candidates. Many of these genes can be linked to major
signaling pathways or have been implicated in EMT and tumor
progression before. We found the HMG-box transcription factor
gene TCF7L1 (also known as TCF3), which can transmit Wnt/b-
Catenin signals [29]. Interestingly, the related transcription factor
TCF7L2 (also known as TCF4) is required to transmit the Wnt/b-
Catenin signal and to maintain the stem cell compartment in the
intestine [47,48]. The family member TCF7L1 is however also
expressed in the colon crypt and in colon cancer (Fig. S8). Our
results therefore indicate that TCF7L1 may have an as yet
unidentified role in transmission of tumor-related b-Catenin
signals.
We also identified PTCH, GLI2 and GLI3, which code for
components of the Hedgehog signaling pathway. Possible roles of
Hedgehog signals in colon cancer progression and metastasis are
controversial [49,50]. Results of our screen support a role of
Hedgehog signals in the modulation of cell adhesion in colon
cancer cells.
Figure 6. FGF9 is expressed in mouse and human intestinal malignancies. Expression of the Wnt target gene Axin2/AXIN2 (to the left) and
Fgf9/FGF9 (to the right) in mouse and human intestinal malignancies was determined by RNA in-situ hybridization. Upper panels: Adenoma of the
colon from an APCmin mouse. Middle panels: primary human colon carcinoma. Lower panel: lung metastasis of human colon carcinoma. Negative
control hybridization (using an unrelated asRNA probe of similar size and CG content, not shown) did not produce a signal. Scale bars represent
500 mm.
doi:10.1371/journal.pone.0023381.g006
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Unexpectedly, the screen yielded also three genes whose
inactivation promoted a more spindle-form phenotype. Two of
these, BICC1 and MAGI1 have been shown before to be required
for the assembly of E-Cadherin-mediated cell adhesion complexes
[51,52]. The finding of functional roles of these genes in the
maintenance of residual cell-cell contacts in tumor cells may
indicate a more universal role for these genes in the regulation of
cell adhesion than anticipated before.
FGF signals have been implicated in the control of intestinal cell
motility and colon cancer progression before. For instance, FGF1
and FGF2 have been shown to promote migration of intestinal
epithelial cells [53], and specific isoforms of FGFR3 can mediate
growth and migration of colon cancer cells [54]. In our screen, we
identified FGF9 as a gene implicated in the regulation of colon
cancer cell adhesion. Using small molecular inhibitors and activity
assays of key signal transducers, we found that the MAPK cascade
and Rho GTPases are critical in the transmission of FGF signals
that control cell adhesion and motility in colon cancer cells, while
the PI3K cascade is not. SW480 colon cancer cells contain a well-
characterized set of mutations, including an activating KRAS
(G12V) mutation [55]. Our data therefore imply that oncogenic
mutations in KRAS do not fully uncouple MAPK activity from
upstream stimuli, but may instead potentiate RTK signal
transduction. In the patient, therapy success using VEGF and
EGF receptor inhibitors depends crucially on the absence of
downstream KRAS or BRAF mutations [25].
Recent models of tumor progression imply an uncontrolled
activation of developmental signaling pathways and embryonic
gene expression programs, resulting in a coordinated loss of cell
adhesion, gain of cell motility and the acquisition of stem cell traits
in metastatic tumor cells [42,43,44]. Our screen identifies multiple
candidate genes that could play roles in these processes. We
furthermore provide evidence that FGF receptor signals in colon
tumor cells can promote pro-metastatic traits by skewing the
balance between cell adhesion and cell motility. In line, we found
that expression of FGF9 in human colon cancer is correlated with
patient’s survival in the limited set of tumors that we examined.
Further studies are required to assess whether FGF9 could serve as
a prognostic factor in colon carcinoma and whether gene
expression programs activated by FGF9 are implicated in the
regulation of tumor cell adhesion, motility and metastasis in
intestinal cancer.
Materials and Methods
esiRNA screen
Human homologues of the selected MAMEP mouse gene entries
were identified using the HomoloGene (NCBI) and Ensembl
(EMBL) databases, and esiRNA preparations were produced for
these genes, as described before [27]. SW480 cells were obtained
from American Type Culture Collection and propagated in DMEM
(Invitrogen), 10% fetal bovine serum. For screening of candidate
Figure 7. FGF9 expression in colon carcinoma correlates with patients’ survival. A Expression of FGF9 or FGFR3 in invasive and metastatic
colon carcinoma, as assessed by microarray analysis (n = 95). Expression in each sample is indicated by circle, median expression in each group is
given by red bar. Numbers in FGF9 graph indicate primary tumor/metastasis pairs derived from the same patient. B Kaplan-Meier survival analysis of
patients examined in A (primary tumors with follow-up data only, n = 39). Patients were grouped according to high (.2-fold of median, indicated by
green circle in Fig. 7A) and low FGF9 and FGFR3 expression.
doi:10.1371/journal.pone.0023381.g007
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genes, SW480 cells were plated at a density of 36104 cells/cm2 onto
glass cover slips, and esiRNAs were transfected in 48-well plates
using Oligofectamine (Invitrogen), essentially as described previously
[27]. esiRNAs against Firefly luciferase and BCL9L were used as
negative and positive controls, respectively, in each plate of the
screen. Representative bright field and E-cadherin immunofluores-
cence (see below) images were taken 72 h after transfection, and
judged independently of each other. Images that displayed unusually
high cell densities were removed from the analysis. Genes were
assigned positives when they scored in both, the bright field and the
immunofluorescence image screen.
Cell-based assays
All colon cancer cell lines were propagated in DMEM, 10% fetal
bovine serum. For scratch wound assays, cells were plated at a
density of 36105/cm2. The following inhibitors were employed:
SU5402 (42 mM), PD173047 (60 mM), U0126 (10 mM), SP600125
(20 mM), Ly294002 (20 mM), and AKT-Inhibitor (30 mM, Calbio-
chem). For immunostaining, cells were washed with PBS, fixed in
4% formaldehyde and permeabilized with 0.5% Triton X-100. The
following antibodies and reagents were used: a-E-Cadherin, a-b-
Catenin (BD), a-RHOA, a-tubulin (Santa Cruz), phalloidin-FITC
(Invitrogen). For Western blotting, the following antibodies were
employed: a-pERK1/2, a-pAKT, a-pPI3K, a-pFGFR (Cell Signal).
For assessment of FGF signaling in SW480, cells were transfected
with a plasmid coding for FGFR1, since the pFGFR1 antibody
employed cannot detect endogenous receptor activity, according to
the manufacturer. For Rho activity assays, SW480 were seeded at
56104 cells/cm2, and serum-starved for 24 h. Rho activity was
assessed 5 min after serum stimulation, using a Rho activation assay
kit (Millipore/Upstate; a-RhoA,B,C antibody) according to manu-
facturer’s protocol. Western blot signals were detected using
chemoluminescence (GE Healthcare) and quantified using ImageJ
software (http://rsbweb.nih.gov/ij). qRT-PCR was done using
random-hexamer primed cDNA prepared according to manufac-
turers’ protocols (Invitrogen), the Step One Plus detection system
and SYBR green. Data was analyzed with Step One Software v2.1
(Applied Biosystems) using the CT(DDCT) method. Marker
expression was normalized to GAPDH as a reference gene. Primer
sequences are available upon request.
Microarray analysis
For microarray analysis, SW480 were treated with DMSO
(solvent control), FGF receptor inhibitor (SU5402), MAPK
Inhibitor (UO126), JNK inhibitor (SP600125), or PI3K inhibitor
(Ly294002) for 24 h as above, using three replicates per treatment
group. RNA was isolated using RNeasy columns (Qiagen), labeled
using the MessageAMP Kit (Ambion), and hybridized to Illumina
Sentrix Hu8-v3 bead chips according to manufacturer’s instruc-
tions. Expression data was processed using Genome Studio GX
software (Illumina), using the cubic spline normalization method
and background subtraction. Non-expressed and marginally
expressed genes were removed for analysis by a detection value
cut-off of 1 in at least 6 out of 15 profiles. Genes were grouped by
self-organising map cluster analysis and visualized using Multi-
Experiment Viewer (http://www.tm4.org). Microarray data are
available via GEO accession number GSE29689.
Histology
For in-situ hybridization, tissues were fixed in 4% formaldehyde,
dehydrated via a graded ethanol series, embedded in paraffin, and
sectioned at 4 mm. In-situ hybridization was performed as
described before [46]. Primer sequences flanking the in-situ probes
are available upon request.
Supporting Information
Figure S1 esiRNA treatment induces effective mRNA
interference in SW480 cells. SW480 cells were transfected
with esiRNAs directed against selected genes or with control
esiRNA, and mRNA levels were assessed 48 h after transfection,
using qRT-PCR. Expression of experimental genes was normal-
ized versus GAPDH. Residual gene expression after specific
esiRNA treatment is given relative to control transfections. Bars
indicate mean of three technical replicates and standard error.
(TIF)
Figure S2 Phenotypic analysis of SW480 and HCT116
colon cancer cells after FGF9 or FGFR3 mRNA interfer-
ence. A RNA interference with FGF9 cells leads to loss of spindle
form and increased membraneous E-cadherin staining in SW480,
confirming the screening result (see Fig. 1B). Silencing of FGFR3
does not induce a visible phenotype in SW480. B Interference with
FGFR3, but not with FGF9, results in loss of spindle form in
HCT116 (see Bright Field), however not to an increase in
membraneous E-cadherin. SW480 and HCT116 were transfected
with Dharmacon smart pool siRNAs, according to manufacturer’s
instructions, using DharmaFECT1 and a final concentration of
25 nM siRNA. Scale bars 50 mm.
(TIF)
Figure S3 Multiple colon cancer cell lines re-epithelialize
upon FGF receptor inhibition. Phenotypes of a panel of colon
cancer cell lines after FGF receptor inhibition, using SU5402.
SW620, HT29 and HCT116 cells show aspects of re-epithelializa-
tion, such as loss of spindle form or disappearance of visible cell-cell
contacts. In contrast, DLD1 (lower panels), WiDr, Caco2 and Cx1
cells (not shown) do not show visible phenotypic alterations after
inhibitor treatment. Images were taken 72 h after start of the
treatment, as in Material and Methods. Scale bar represents 50 mm.
(TIF)
Figure S4 Inhibition of MEK1/2 by U0126 induces re-
epithelialization and blocks cell motility in SW480 cells.
Left: Phenotypic switch of SW480 cells upon MEK1/2 inhibition.
Top to bottom: Cell morphology in phase contrast, immunoflu-
orescence of E-cadherin and b-Catenin, which are components of
adherens junctions. Photos were taken 72 h after start of the
treatment. Right: Scratch-wound motility assay upon MEK1/2
inhibition. SW480 cells were grown to confluence, and scratches
were induced 24 h after start of inhibitor treatment. Photos show
phase-contrast images of the scratch edge and were taken 24, 48
and 72 hour after scratching. Red line indicates scratch edge, blue
line indicates cell migration front. Scale bars represent 50 mm.
(TIF)
Figure S5 Phenotypic effects of inhibitor treatment in
HCT116 colon cancer cells. Scratch-wound assays were
performed upon inhibition of FGF receptors, MEK1/2, JNK or
AKT, as indicated. HCT116 cells were grown to confluence, and
scratches were induced 24 h after start of treatment. Solvent
control-treated cells, as well as AKT- inhibitor-treated cells close
the scratch wound, whereas FGFR, MEK1/2 or JNK inhibitor
treatments lead to a delay in scratch wound closure. Inhibition of
PI3K leads to marked loss of cells at the scratch edge (not shown).
Bright field images of the scratch were taken 72 hour after
scratching. Red line indicates scratch edge, blue line indicates cell
migration front. Scale bar represents 100 mm.
(TIF)
Figure S6 Ingenuity pathway analysis identifies a net-
work implicated in cellmotility, which is enriched in FGF-
FGF Signals in Colon Cancer Progression
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23381
regulated genes. Green: downregulated genes after SU5402
treatment, red: upregulated genes after SU5402 treatment. Grey:
non-regulated genes within the network. Network was derived from
genes deregulated (.1.3-fold, p,0.05) in expression profiles from
biological triplicates of SU5402-treated SW480 cells and solvent
controls. Profiles were normalized in Illumina Genome Studio using
cubic spline normalization and background subtraction. Absent and
marginally expressed genes were removed before analysis.
(TIF)
Figure S7 An SW480-derived gene expression program
associated with epithelial and mesenchymal morpholo-
gy is also modulated in HCT116 cells. Analysis of gene
expression in HCT116, 24 h after treatment with SU5402 or in
solvent control (DMSO). Figure shows genes whose expression has
previously been identified to correlate with mesenchymal or
epithelial phenotypes in SW480 cells (see Fig. 5A). Genes that are
not expressed in HCT116 were removed. Gene expression profiles
were assessed using Illumina Sentrix Hu8-v2 bead chips according
to manufacturer’s instructions. Data was processed from biological
duplicates using Illumina Genome Studio, as detailed in the
Material and Methods section. Red indicates high expression; blue
low expression and white average expression.
(TIF)
Figure S8 TCF7L1 expression is delocalized and upre-
gulated in human colon carcinoma. Expression of TCF7L1
in normal human colon (upper panel), primary human colon
carcinoma (middle panel), and lung metastasis of human colon
carcinoma (lower panel), as assessed by RNA in-situ hybridization.
Negative control hybridization (using an unrelated asRNA probe
of similar size and CG content) did not produce a signal (not
shown).
(TIF)
Table S1 Full list of genes that were targeted by esiRNA
in the loss-of-function phenotypic screen. Table gives Gene
Symbols, ENSEMBL IDs, esiRNA information and comments on
screening results. Bold Gene Symbols correspond to current
ENSEMBL IDs (GRCh37.p3, release 62), Gene Symbols in
regular type may correspond to previous builds.
(XLS)
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